Breaking Finance News

Zacks Investment Research reported on Reata Pharmaceuticals Inc (NASDAQ:RETA), upping its target price to $30.00 earlier today

Just yesterday Reata Pharmaceuticals Inc (NASDAQ:RETA) traded -10.85% lower at $28.70. Reata Pharmaceuticals Inc’s 50-day moving average is $21.09 and its 200-day moving average is $19.44. The last stock price is up 18.80% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 502,668 shares of RETA traded hands, up from an average trading volume of 119,753

Zacks Investment Research bumped up the target of Reata Pharmaceuticals Inc (NASDAQ:RETA) to $30.00 reporting a possible upside of 0.05%.

Recent Performance Chart

Reata Pharmaceuticals Inc (NASDAQ:RETA)

Reata Pharmaceuticals Inc has 52 week low of $11.03 and a 52 week high of $32.22 and has a market capitalization of $0.

Brief Synopsis On Reata Pharmaceuticals Inc (NASDAQ:RETA)

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates, bardoxolone methyl and RTA 408, are members of a class of small molecules called antioxidant inflammation modulators (AIMs). The Company's Bardoxolone methyl is an AIM, which targets the bioenergetic and inflammatory components of pulmonary hypertension (PH), which can improve functional capacity in patients suffering from certain forms of this disease. The Company's RTA 408 is a close structural analog of bardoxolone methyl that was developed to improve tissue distribution, including blood-brain barrier penetration.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.